Jianli Dong is a Professor and Director of the Molecular
Diagnostics Division, Department of Pathology, The University of Texas Medical
Branch at Galveston. She received an MD from Southern Medical University in
1985 and completed residency at Beijing Institute of Infectious Diseases in
1987. She also obtained an MSc in Molecular Biology in 1992 and a PhD in Genetics
from the University of Toronto in 1998. She served as a Research Fellow in
Human Genetics at Yale University School of Medicine and as a Clinical Fellow
in Clinical Molecular Genetics at Mount Sinai School of Medicine in 2001. She
is a fellow of the American College of Medical Genetics and Genomics (ACMG) and a member of the Association for Molecular Pathology (AMP). She is most interested in research, development,
and validation studies of laboratory genetics and genomics assays to
improve the diagnosis and management of human diseases. She is also interested
in BRAF-MEK-ERK and p16-CDK4/6-RB pathways in cancer biology and as therapeutic
targets in melanoma and other cancers.
Jianli Dong is a Professor and Director of the Molecular
Diagnostics Division, Department of Pathology, The University of Texas Medical
Branch at Galveston. She received an MD from Southern Medical University in
1985 and completed residency at Beijing Institute of Infectious Diseases in
1987. She also obtained an MSc in Molecular Biology in 1992 and a PhD in Genetics
from the University of Toronto in 1998. She served as a Research Fellow in
Human Genetics at Yale University School of Medicine and as a Clinical Fellow
in Clinical Molecular Genetics at Mount Sinai School of Medicine in 2001. She
is a fellow of the American College of Medical Genetics and Genomics (ACMG) and a member of the Association for Molecular Pathology (AMP). She is most interested in research, development,
and validation studies of laboratory genetics and genomics assays to
improve the diagnosis and management of human diseases. She is also interested
in BRAF-MEK-ERK and p16-CDK4/6-RB pathways in cancer biology and as therapeutic
targets in melanoma and other cancers.